News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Gilead (GILD) Might Do 'Nothing In Oncology' As Key Drugs Topple



8/11/2017 8:17:21 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Gilead Sciences (GILD) "might end up doing nothing in oncology" if the right takeover deal doesn't present itself, Chief Executive John Milligan reportedly told an analyst Wednesday.

The third-largest biotech by market cap, Gilead has struggled with declining sales of hepatitis C drugs for several quarters. In the first quarter, Gilead hinted that it could be looking to buy an oncology player. But Gilead remained mum on a potential merger in the recent second quarter.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES